Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94924162 | 9492416 | 2 | F | 20160720 | 20130830 | 20160720 | EXP | JP-BRISTOL-MYERS SQUIBB COMPANY-19229533 | BRISTOL MYERS SQUIBB | SEVERE HAEMORRHAGES ASSOCIATED WITH SUSPECTED INTERACTION BETWEEN ANTIRHEUMATIC LGURATIMOD AND WARFARIN. PHARMACEUTICALS AND MEDICAL DEVICES SAFETY INFORMATION. 2013;5-8 | 8.00 | DEC | M | Y | 0.00000 | 20160720 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94924162 | 9492416 | 1 | PS | WARFARIN SODIUM. | WARFARIN SODIUM | 1 | Unknown | U | 9218 | ||||||||||
| 94924162 | 9492416 | 2 | I | IGURATIMOD | IGURATIMOD | 1 | Oral | 25 MG, QD | Y | 0 | 25 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 94924162 | 9492416 | 1 | Product used for unknown indication |
| 94924162 | 9492416 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 94924162 | 9492416 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 94924162 | 9492416 | Conjunctival haemorrhage | |
| 94924162 | 9492416 | Drug interaction | |
| 94924162 | 9492416 | Puncture site haemorrhage |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |